Trial Profile
Observational study to examine the usefulness of denosumab in postmenopausal breast cancer patients
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 May 2019
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone metastases; Postmenopausal osteoporosis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 03 May 2019 Status changed from suspended to discontinued.
- 09 Dec 2018 Status changed from recruiting to suspended.
- 05 May 2015 New trial record